Quality assessment of compounded 17-hydroxyprogesterone caproate

American Journal of Obstetrics and Gynecology

Volumn 210, Issue 1, 2014, Pages 47.e1-47.e7

  Chang, Justine ^a   Zhao, Yang ^b   Zhao, Wenchen ^b   Venkataramanan, Raman ^b   Caritis, Steve N ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

compounded 17 OHPC; impurity analysis; potency; sterility and pyrogen status

Indexed keywords

BENZYL ALCOHOL; BENZYL BENZOATE; CASTOR OIL; HEXANOIC ACID; HYDROXYPROGESTERONE CAPROATE; PYROGEN;

ARTICLE; DRUG FORMULATION; DRUG IMPURITY; DRUG POTENCY; DRUG QUALITY; DRUG STERILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PHARMACY; PRIORITY JOURNAL; QUALITY CONTROL; UNITED STATES;

EID: 84890833559     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2013.09.039     Document Type: Article

References (13)

1. P.J. Meis, M. Klebanoff, and E. Thom et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network: prevention of recurrent preterm delivery by 17 alpha- hydroxyprogesterone caproate N Engl J Med 348 2003 2379 2385
2. Food and Drug Administration. FDA statement on Makena, Nov. 8, 2011. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm279098.htm. Accessed Aug. 27, 2013.
3. March of Dimes. Statement from the March of Dimes on 17P. Available at: http://www.marchofdimes.com/news/statement-from-the-march-of-dimes-on-17p.aspx. Accessed Aug. 27, 2013.
4. Gunter J. March of Dimes response to Makena pricing reveals they are woefully out of touch. Available at: http://www.preemieprimer.com/march-of- dimes-response-to-makena-pricing-reveals-they-are-woefully-out-of-touch/. Accessed Aug. 27, 2013.
5. Sherrod Brown, Senator for Ohio. Following Makena price hike controversy, Brown asks NIH director: how can we stop drug manufacturers from exploiting. Available at: http://www.brown.senate.gov/newsroom/press/release/following- makena-price-hike-controversy-brown-asks-nih-director-how-can-we-stop-drug- manufacturers-from-exploiting-taxpayer-funded-research. Accessed Aug. 28, 2013.
6. Food and Drug Administration. FDA statement on Makena, March 30, 2011 Available at: http://www.fda.gov/newsEvents/Newsroom/PressAnnouncements/ ucm249025.htm. Accessed Aug. 27, 2013.
7. J.L. Chollet, and M.J. Jozwiakowski Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection Drug Dev Ind Pharm 38 2012 540 549
8. Food and Drug Administration. Updated FDA statement on compounded versions of hydroxyprogesterone caproate (the active ingredient in Makena) Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm308546.htm. Accessed Aug. 27, 2013.
9. S.N. Caritis, Y. Zhao, and J. Bettinger et al. Qualitative and quantitative measures of various compounded formulations of 17-alpha hydroxyprogesterone caproate Am J Obstet Gynecol 208 2013 470.e1 470.e5 74-80
10. Eagle Analytical ServicesvRapid Scan RDI-Bacteria, mold, and fungal test. Available at: http://www.eagleanalytical.com/sitecontent/589/rapid-scan-rdi- bacteria-mold-and-fungal-test/category/462/about-testing.aspx. Accessed Aug. 27, 2013.
11. Eagle Analytical Services. Endotoxins. http://www.eagleanalytical.com/ sitecontent/588/endotoxins/category/462/about-testing.aspx. Accessed August 27, 2013.
12. Food and Drug Administration. 17 alpha hydroxyprogesterone caproate injection, NDA 21-9435. Adeza Biomedical Advisory Committee Meeting, Aug. 9, 2006. Available at: www.fda.gov/ohrms/dockets/ac/06/slides/2006-4227S1-01-01- Adeza.pdf. Accessed Aug. 27, 2013.
13. American College of Obstetricians and Gynecologists. ACOG/SMFM update on New England compounding center. Available at: http://www.acog.org/About-ACOG/ Announcements/ACOG-SMFM-Update-on-New-England-Compounding-Center. Accessed Aug. 27, 2013.